NO20081266L - 4- (4-Brom-2-Fluoranilino) -6-Metoksy-7- (1-Metylpiperidin-4 -Ylmetoksy) kinazolinmonohydrate - Google Patents

4- (4-Brom-2-Fluoranilino) -6-Metoksy-7- (1-Metylpiperidin-4 -Ylmetoksy) kinazolinmonohydrate

Info

Publication number
NO20081266L
NO20081266L NO20081266A NO20081266A NO20081266L NO 20081266 L NO20081266 L NO 20081266L NO 20081266 A NO20081266 A NO 20081266A NO 20081266 A NO20081266 A NO 20081266A NO 20081266 L NO20081266 L NO 20081266L
Authority
NO
Norway
Prior art keywords
monohydrate
fluoroanilino
ylmethoxy
methylpiperidin
bromo
Prior art date
Application number
NO20081266A
Other languages
English (en)
Inventor
Rebecca Jane Booth
Brian Roger Meyrick
Zakariya Patel
Richard Anthony Storey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081266(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20081266L publication Critical patent/NO20081266L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår et ZD6474 monohydrat, fremgangsmåter for fremstilling av et ZD6474 monohydrat, farmasøytiske preparater omfattende et ZD6474 monohydrat som den aktive bestanddel, anvendelse av et ZD6474 monohydrat ved fremstilling av medikamenter for anvendelse for produksjon av antiangiogene og/eller vaskulære permeabilitets-reduserende effekter hos varmblodige dyr så som mennesker og anvendelse av et ZD6474 monohydrat ved metoder for behandling av sykdomstilstander forbundet med angiogenese og/eller øket vaskulær permeabilitet, så som kreft, hos varmblodige dyr så som mennesker.
NO20081266A 2005-09-30 2008-03-11 4- (4-Brom-2-Fluoranilino) -6-Metoksy-7- (1-Metylpiperidin-4 -Ylmetoksy) kinazolinmonohydrate NO20081266L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519878.3A GB0519878D0 (en) 2005-09-30 2005-09-30 Chemical compound
PCT/GB2006/003594 WO2007036717A1 (en) 2005-09-30 2006-09-27 4- (4-BROMO-2-FLUOROANILINO) -6-METHOXY-7- (l-METHYLPIPERIDIN-4 -YLMETHOXY) QUINAZOLINE MONOHYDRATE

Publications (1)

Publication Number Publication Date
NO20081266L true NO20081266L (no) 2008-06-27

Family

ID=35395000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081266A NO20081266L (no) 2005-09-30 2008-03-11 4- (4-Brom-2-Fluoranilino) -6-Metoksy-7- (1-Metylpiperidin-4 -Ylmetoksy) kinazolinmonohydrate

Country Status (16)

Country Link
US (1) US20080312261A1 (no)
EP (1) EP1937665A1 (no)
JP (1) JP2009510040A (no)
KR (1) KR20080059276A (no)
CN (1) CN101277947A (no)
AR (1) AR056557A1 (no)
AU (1) AU2006296371A1 (no)
BR (1) BRPI0616583A2 (no)
CA (1) CA2623646A1 (no)
GB (1) GB0519878D0 (no)
IL (1) IL190010A0 (no)
NO (1) NO20081266L (no)
TW (1) TW200745083A (no)
UY (1) UY29822A1 (no)
WO (1) WO2007036717A1 (no)
ZA (1) ZA200802640B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
CN100376567C (zh) * 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物

Also Published As

Publication number Publication date
AR056557A1 (es) 2007-10-10
CA2623646A1 (en) 2007-04-05
WO2007036717A1 (en) 2007-04-05
GB0519878D0 (en) 2005-11-09
CN101277947A (zh) 2008-10-01
JP2009510040A (ja) 2009-03-12
AU2006296371A1 (en) 2007-04-05
US20080312261A1 (en) 2008-12-18
IL190010A0 (en) 2008-08-07
UY29822A1 (es) 2007-04-30
BRPI0616583A2 (pt) 2011-06-21
ZA200802640B (en) 2010-09-29
EP1937665A1 (en) 2008-07-02
KR20080059276A (ko) 2008-06-26
WO2007036717A8 (en) 2008-03-27
TW200745083A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
NO20062703L (no) Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel
CY1121070T1 (el) Φαρμακευτικες συνθεσεις για την αγωγη cftr μεσολαβουμενων παθησεων
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
NO20084257L (no) Diketopiperazin og piperidin derivater som antivirale midler
NZ597551A (en) Pyridine and pyrazine derivatives as protein kinase modulators
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
NO332405B1 (no) Forbindelse av 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling, deres anvendelse til fremstilling av farmasoytiske midler for behandling av inflammatorisk sykdom og farmasoytisk preparat omfattende forbindelsen.
ATE534292T1 (de) Spiroverbindungen und anwendungsverfahren dafür
TW200628451A (en) Novel pyrimidine derivatives and their use
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
NO20081267L (no) Fremgangsmåte for fremstilling av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin, ZD6474
EP2583962A4 (en) NOVEL THIOURED OR NEW UREA DERIVATIVE, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING THE SAME AS ACTIVE INGREDIENT
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
IL284930A (en) History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases
TNSN08279A1 (en) Bayer healthcare ag
NO20052803L (no) Komplekser av e-2-metoksy-n-(3-{4-(3-metyl-pyridin-3-yloksy)-fenylam ino)-kinazolin-6-yl}-allyl)acetamid, deres fremstillingsmate og bruk
NO20081266L (no) 4- (4-Brom-2-Fluoranilino) -6-Metoksy-7- (1-Metylpiperidin-4 -Ylmetoksy) kinazolinmonohydrate
UA107088C2 (xx) 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
MX2015013625A (es) Nuevo derivado oxazolidina como inhibidor de la proteina de transferencia del ester de colesterilo (cetp), su metodo de preparacion, y composicion farmaceutica que lo comprende.
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application